Peregrine Pharmaceuticals Inc. | Stock Market News & Stocks to Watch from StraightStocks

DrStockPick.com Stock Report! 11/03/09, CVAT, MCBC, ITW, PPHMD, GPK, ALK

Dr. Stock Pick (November 3rd, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday November 3, 2009

DrStockPick.com Stock Report!

**************************************************************

Cavitation Technologies, Inc. (OTC Bulletin Board: CVAT) announced recently that it has signed Miura Engineering Co., Ltd. Tokyo, Japan (www.miura21.co.jp) as its new agent to serve markets in Japan for CTI’s Nano-Cavitation Process Systems. Miura is a leading Engineering Company specialized in Edible Oil Processing Plants in the Far East. Last week CVAT reported a 3-for-1 forward stock split.

The Board of Directors of Macatawa Bank (Nasdaq:MCBC) has selected Richard L. Postma, a successful and respected

...

Tags for this Post:
advertisement services, advertising services, Alaska Air Group Inc, Alaska Airlines Inc.;, Altivity Packaging LLC, Cavitation Process Systems, Cavitation Technologies Inc., Chairman, Chairman and Chief Executive Officer, Chicago, Crown Equity Holdings Inc.;, David B. Speer, Dr Stock Pick, Far East, Four Seasons hotel, Graphic Packaging Holding Company, Graphic Packaging International Inc., Horizon Air Industries Inc., Illinois, Illinois Tool Works Inc., Investing Lessons, Japan, Macatawa Bank Corp, Miura Engineering Co. Ltd., Nasdaq 100, NASDAQ Market Listing Qualifications Department, New York, new york stock exchange, Peregrine Pharmaceuticals Inc., Richard L. Postma, Robert W. Baird, stock featured on our site;, Stocks to Watch, successful and respected business leader, Tokyo, United States, www.alaskaair.com/investors, www.miura21.co.jp

Posted in Investing Lessons, Stocks to Watch | No Comments »

Peregrine Pharmaceuticals Inc. (PPHM) to Manufacture Human Coagulation Factor Clinical Candidate for Catalyst Biosciences

QualityStocks (October 28th, 2008) Writes:

Avid Bioservices is a wholly owned subsidiary of Peregrine Pharmaceuticals Inc. Avid Bioservices has signed a manufacturing supply agreement with Catalyst Biosciences, Inc. to produce clinical-grade material in support of their clinical candidate, CB 813, an improved version of factor VIIa for the treatment of acute bleeding in hemophilia patients.

Hemophilia is a hereditary disorder that affects approximately one in 5,000 males born in the United States. When a person with hemophilia is injured, he does not bleed harder or faster than a person without hemophilia, he bleeds longer. Small cuts or surface bruises are usually not a problem, but more traumatic injuries may result in serious problems and potential disability. Deep cuts or internal bleeding, such as bleeding into the joints or muscles, require more complex treatment. The clotting factor missing (VIII or IX) must be replaced so individual can form a clot to stop the bleeding.

Under the

...